Systems pathology

Breast Cancer Research

Volumn 12, Issue SUPPL. 4, 2010, Pages

  Faratian, Dana ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; TUMOR MARKER; ANTINEOPLASTIC AGENT;

ARTICLE; BREAST CANCER; CANCER THERAPY; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; PROGNOSIS; BREAST TUMOR; CLINICAL PROTOCOL; DRUG RESISTANCE; FEMALE; GENETICS; HISTOLOGY; PATHOLOGY;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC PROTOCOLS; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; HISTOLOGICAL TECHNIQUES; HUMANS; PROGNOSIS; RECEPTOR, ERBB-2; TUMOR MARKERS, BIOLOGICAL;

EID: 78650882233     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr2733     Document Type: Article

References (31)

1. Payne SJ, Bowen RL, Jones JL, Wells CA. Predictive markers in breast cancer - the present. Histopathology 2008, 52:82-90. 10.1111/j.1365-2559.2007.02897.x, 18171419.
2. Dowsett M, A'Hern R, Salter J, Zabaglo L, Smith IE. Who would have thought a single Ki67 measurement would predict long-term outcome?. Breast Cancer Res 2009, 11(Suppl 3):S15. 2797695, 20030866, 10.1186/bcr2434.
3. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998, 4:844-847. 10.1038/nm0798-844, 9662379.
4. Lord CJ, Ashworth A. Biology-driven cancer drug development: back to the future. BMC Biol 2010, 8:38. 2864096, 20385032, 10.1186/1741-7007-8-38.
5. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lønning PE, Børresen-Dale AL, Brown PO, Botstein D. Molecular portraits of human breast tumours. Nature 2000, 406:747-752. 10.1038/35021093, 10963602.
6. Reis-Filho JS, Tutt AN. Triple negative tumours: a critical review. Histopathology 2008, 52:108-118. 10.1111/j.1365-2559.2007.02889.x, 18171422.
7. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher ER, Wickerham DL, Bryant J, Wolmark N. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004, 351:2817-2826. 10.1056/NEJMoa041588, 15591335.
8. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005, 353:1673-1684. 10.1056/NEJMoa052122, 16236738.
9. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Láng I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Rüschoff J, Suto T, Greatorex V, Ward C, Straehle C, McFadden E, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005, 353:1659-1672. 10.1056/NEJMoa052306, 16236737.
10. Faratian D, Clyde RG, Crawford JW, Harrison DJ. Systems pathology - taking molecular pathology into a new dimension. Nat Rev Clin Oncol 2009, 6:455-464. 10.1038/nrclinonc.2009.102, 19581910.
11. De P, Leyland-Jones B. Whither HER2-related therapeutics?. J Clin Oncol 2010, 28:1091-1096. 10.1200/JCO.2009.25.8624, 20124168.
12. Simon RM, Paik S, Hayes DF. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 2009, 101:1446-1452. 2782246, 19815849, 10.1093/jnci/djp335.
13. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer 2005, 93:387-391. 2361579, 16106245, 10.1038/sj.bjc.6602678.
14. Camp RL, Chung GG, Rimm DL. Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med 2002, 8:1323-1327. 10.1038/nm791, 12389040.
15. NCCN Guideline and Clinical Resources. , http://www.nccn.org/JNCCN/supplements.asp
16. Henney A, Superti-Furga G. A network solution. Nature 2008, 455:730-731. 10.1038/455730a, 18843342.
17. Faratian D, Moodie SL, Harrison DJ, Goryanin I. Dynamic computational modeling in the search for better breast cancer drug therapy. Pharmacogenomics 2007, 8:1757-1761. 10.2217/14622416.8.12.1757, 18086005.
18. Hornberg JJ, Bruggeman FJ, Westerhoff HV, Lankelma J. Cancer: a systems biology disease. Biosystems 2006, 83:81-90. 10.1016/j.biosystems.2005.05.014, 16426740.
19. Aitken SJ, Thomas JS, Langdon SP, Harrison DJ, Faratian D. Quantitative analysis of changes in ER, PR and HER2 expression in primary breast cancer and paired nodal metastases. Ann Oncol 2010, 21:1254-1261. 10.1093/annonc/mdp427, 19858088.
20. Noble D. Systems biology and the heart. Biosystems 2006, 83:75-80. 10.1016/j.biosystems.2005.05.013, 16233947.
21. Noble D, Noble PJ. Late sodium current in the pathophysiology of cardiovascular disease: consequences of sodium-calcium overload. Heart 2006, 92(Suppl 4):iv1-iv5. 1861316, 16775091, 10.1136/hrt.2005.078782.
22. O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, Lane H, Hofmann F, Hicklin DJ, Ludwig DL, Baselga J, Rosen N. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006, 66:1500-1508. 10.1158/0008-5472.CAN-05-2925, 16452206.
23. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates?. Nat Rev Drug Discov 2004, 3:711-715. 10.1038/nrd1470, 15286737.
24. Faratian D, Goltsov A, Lebedeva G, Sorokin A, Moodie S, Mullen P, Kay C, Um IH, Langdon S, Goryanin I, Harrison DJ. Systems biology reveals new strategies for personalizing cancer medicine and confirms the role of PTEN in resistance to trastuzumab. Cancer Res 2009, 69:6713-6720. 10.1158/0008-5472.CAN-09-0777, 19638581.
25. Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, Beelen K, Linn SC, Gonzalez-Angulo AM, Stemke-Hale K, Hauptmann M, Beijersbergen RL, Mills GB, van de Vijver MJ, Bernards R. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 2007, 12:395-402. 10.1016/j.ccr.2007.08.030, 17936563.
26. Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA, Klos KS, Li P, Monia BP, Nguyen NT, Hortobagyi GN, Hung MC, Yu D. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004, 6:117-127. 10.1016/j.ccr.2004.06.022, 15324695.
27. Birtwistle MR, Hatakeyama M, Yumoto N, Ogunnaike BA, Hoek JB, Kholodenko BN. Ligand-dependent responses of the ErbB signaling network: experimental and modeling analyses. Mol Syst Biol 2007, 3:144. 2132449, 18004277, 10.1038/msb4100188.
28. Kholodenko BN, Demin OV, Moehren G, Hoek JB. Quantification of short term signaling by the epidermal growth factor receptor. J Biol Chem 1999, 274:30169-30181. 10.1074/jbc.274.42.30169, 10514507.
29. Moehren G, Markevich N, Demin O, Kiyatkin A, Goryanin I, Hoek JB, Kholodenko BN. Temperature dependence of the epidermal growth factor receptor signaling network can be accounted for by a kinetic model. Biochemistry 2002, 41:306-320. 10.1021/bi011506c, 11772030.
30. Schoeberl B, Eichler-Jonsson C, Gilles ED, Muller G. Computational modeling of the dynamics of the MAP kinase cascade activated by surface and internalized EGF receptors. Nat Biotechnol 2002, 20:370-375. 10.1038/nbt0402-370, 11923843.
31. Desta Z, Ward BA, Soukhova NV, Flockhart DA. Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther 2004, 310:1062-1075. 10.1124/jpet.104.065607, 15159443.